1Garraway WM,Collins GN,Lee LJ.High prevalence of benign prostatic hyperplasia in the community. Lancet,1991,338:469-471.
2Neutel CI,Gao RN,Blood PA. The changing age distribution of prostate cancer in Canada[J].Canadian Journal of Public Health-Revue Canadienne De Sante Publique,2007,(01):60-64.
3Chaly Y, Marinov AD, Oxburgh L, et al. FSTL1 promotes arthritisin mice by enhancing inflammatory cytokine/chemokine expression[J].Arthritis R heum, 2012,64 (4 ) : 1082-1088.
4Salagierski M, Schalken JA. Molecular diagnosis of prostate cancer:PCA3andTMP R SS2: ERG gene fusiontJ]. J Urol, 2012,187(3):795-801.
5Su Y,Gao L, Teng L, et al. Idl enhances human ovarian cancer andendothelial progenitor cell angiogenesis via PI3K/AKt and NF-kappaB/MMP-2 signaling pathways[J]. J Transl Med,2013, 11 : 132.
6Gumulec J, Masarik M, Krizkova S, et al. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigenas prostate cancer prognostic markersfj]. Neoplasma,2012, 59 ( 2 ):191-201.
7Li D, Wang Y, Xu N, et al. Follistatin-like protein 1 is elevated insystemic autoimmune diseases and correlated with disease activity inpatients with rheumatoid arthritis[J]. Arthritis Res Ther, 2011,13 ( 1 ):R17.
